CoChat
Sign Up
Cited by 316MicroRNA in disease regulationCancer-related molecular mechanisms researchLung Cancer Diagnosis and Treatment

Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer

Open access
Xie, Ying, Todd, Nevins W., Liu, Zhenqiu, Zhan, Min, Fang, HongBin, Peng, Hong, Alattar, Mohammed, Deepak, Janaki +2 more·2010·Lung Cancer
DOI 10.1016/j.lungcan.2009.04.004PMC PMC2846426
Open this paper in CoChat — free account

Abstract

Unlabelled Analysis of molecular genetic markers in biological fluids has been proposed as a useful tool for cancer diagnosis. MicroRNAs (miRNAs) are small regulatory RNAs that are frequently dysregulated in lung cancer and have shown promise as tissue-based markers for its prognostication. The aim of this study was to determine whether aberrant miRNA expression can be used as a marker in sputum specimen for the diagnosis of non-small cell lung cancer (NSCLC). Experimental design expressions of mature miRNAs, mir-21 and mir-155, were examined by real-time reverse transcription polymerase chain reaction (RT-PCR) and normalized to that of control miRNA, U6B, in sputum of 23 patients with NSCLC and 17 cancer-free subjects. The data was compared with conventional sputum cytology for the diagnosis of lung cancer. All endogenous miRNAs were present in sputum in a remarkably stable form and sensitively and specifically detected by real-time RT-PCR. Mir-21 expression in the sputum specimens was significantly higher in cancer patients (76.32+/-9.79) than cancer-free individuals (62.24+/-3.82) (P<0.0001). Furthermore, overexpression of mir-21 showed highly discriminative receiver-operator characteristic (ROC) curve profile, clearly distinguishing cancer patients from cancer-free subjects with areas under the ROC curve at 0.902+/-0.054. Detection of mir-21 expression produced 69.66% sensitivity and 100.00% specificity in diagnosis of lung cancer, as compared with 47.82% sensitivity and 100.00% specificity by sputum cytology. The measurement of altered miRNA expression in sputum could be a useful noninvasive approach for the diagnosis of lung cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.lungcan.2009.04.004

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The level of miR-21 expression in sputum distinguishes NSCLC patients from cancer-free controls with a greater sensitivity than conventional cytology.

    “The level of miR-21 expression in sputum distinguishes NSCLC patients from cancer-free controls with a greater sensitivity than conventional cytology (Xie et al., 2009).”

    From Modulation of K-Ras-Dependent Lung Tumorigenesis by MicroRNA-21 (2010) · cites this paper as Xie et al., 2009

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 21

  1. [1]Greenlee RT Hill-Harmon MB Murray T Thun M Cancer statistics, 2001 CA Cancer J Clin 2001 51 15 36 11577478
  2. [2]Flehinger BJ Melamed MR Zaman MB Heelan RT Perchick WB Martini N Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study Am Rev Respir Dis 1984 130 549 554 6091506
  3. [3]Hirsch FR Franklin WA Gazdar AF Bunn PA Jr Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology Clin Cancer Res 2001 7 5 22 11205917
  4. [4]Toloza EM Harpole L McCrory DC Noninvasive staging of non-small cell lung cancer: a review of the current evidence Chest 2003 123 137S 146S 12527573
  5. [5]Minna JD Roth JA Gazdar AF Focus on lung cancer Cancer Cell 2002 1 49 52 12086887
  6. [6]Saccomanno G Archer VE Auerbach O Saunders RP Brennan LM Development of carcinoma of the lung as reflected in exfoliated cells Cancer 1974 33 256 70 4810100
  7. [7]Thunnissen FB Sputum examination for early detection of lung cancer J Clin Pathol 2003 11 805 10 14600122 PMC1770101
  8. [8]Li R Todd NW Qiu Q Fan T Zhao RY Rodgers WH Genetic deletions in sputum as diagnostic markers for early detection of stage I non-small cell lung cancer Clin Cancer Res 2007 13 482 7 17255269
  9. [9]Qiu Q Todd NW Li R Peng H Liu Z Yfantis HG Katz RL Stass SA Jiang F Magnetic enrichment of bronchial epithelial cells from sputum for lung cancer diagnosis Cancer 2008 114 275 83 18484646 PMC4255556
  10. [10]Lagos-Quintana M Rauhut R Lendeckel W Tuschl T Identification of novel genes coding for small expressed RNAs Science 2001 294 853 8 11679670
  11. [11]Yanaihara N Caplen N Bowman E Seike M Kumamoto K Yi M Unique microRNA molecular profiles in lung cancer diagnosis and prognosis Cancer Cell 2006 9 189 98 16530703
  12. [12]Ortholan C Puissegur MP Ilie M Barbry P Mari B Hofman P MicroRNAs and Lung Cancer: New Oncogenes and Tumor Suppressors, New Prognostic Factors and Potential Therapeutic Targets Curr Med Chem 2009 16 1047 61 19275611
  13. [13]Takamizawa J Konishi H Yanagisawa K Tomida S Osada H Endoh H Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival Cancer Res 2004 64 3753 6 15172979
  14. [15]Saccomanno G Archer VE Auerbach O Saunders RP Brennan LM Development of carcinoma of the lung as reflected in exfoliated cells Cancer 1974 33 256 70 4810100
  15. [16]Chen C Ridzon DA Broomer AJ Zhou Z Lee DH Nguyen JT Real-time quantification of microRNAs by stem-loop RT-PCR Nucleic Acids Res 2005 33 e179 16314309 PMC1292995
  16. [17]Mitchell PS Parkin RK Kroh EM Fritz BR Wyman SK Pogosova-Agadjanyan EL Circulating microRNAs as stable blood-based markers for cancer detection Proc Nat Acad Sci USA 2008 105 10513 8 18663219 PMC2492472
  17. [18]Chan JA Krichevsky AM Kosik KS MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells Cancer Res 2005 65 6029 33 16024602
  18. [19]Pezzolesi MG Platzer P Waite KA Eng C Differential expression of PTEN-targeting microRNAs miR-19a and miR-21 in Cowden syndrome Am J Hum Genet 2008 82 1141 9 18460397 PMC2427229
  19. [20]Zhu S Si ML Wu H Mo YY MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1) J Biol Chem 3007 282 14328 36 17363372
  20. [21]Gironella M Seux M Xie MJ Cano C Tomasini R Gommeaux J Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development Proc Nat Acad Sci USA 2007 104 16170 5 17911264 PMC2042180
  21. [22]Nikiforova MN Tseng GC Steward D Diorio D Nikiforov YE MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility J Clin Endocr Metab 2008 93 1600 1608 18270258 PMC2386678

Cited by

Sorted by citations

Authors
Xie, Y., Todd, N. W., Liu, Z., Zhan, M., Fang, H., Peng, H., Alattar, M., Deepak, J., Stass, S. A., & Jiang, F.
Affiliations
University of Maryland, Baltimore (US)
Corresponding author
Jiang, Feng
ORCID
Venue
Lung Cancer
Publisher
Elsevier BV
Published
2010-02
Volume
67
Issue
2
Pages
170-176
ISSN
0169-5002 (ISSN-L)
DOI
10.1016/j.lungcan.2009.04.004
PMC
PMC2846426
OpenAlex
W2080384607
Cited by
316
References
1
Citations by year
2026: 1 · 2025: 6 · 2024: 8 · 2023: 10 · 2022: 10 · 2021: 15 · 2020: 21 · 2019: 19 · 2018: 26 · 2017: 18 · 2016: 22 · 2015: 23 · 2014: 32 · 2013: 35 · 2012: 29
FWCI
7.83
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Lung Cancer (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (5k12rr023250-05)
  • National Cancer Institute (CA137742, R21CA135382, R03CA133956, CA135382, R03CA137742, CA-133956)
  • National Center for Research Resources (K12-RR023250)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords
non-small cell lung cancer, microRNA, sputum, miR-21, miR-155, liquid biopsy, cancer diagnosis, non-invasive biomarkers, sputum cytology, sensitivity and specificity
MeSH terms
Aged, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Neoplasm Staging, ROC Curve, Sensitivity and Specificity, Sputum, Biomarkers, Tumor, Area Under Curve, Reverse Transcriptase Polymerase Chain Reaction, RNA Stability, MicroRNAs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review